الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 122 |  |  |
| | | from | 122 | | |
Abstract
Breast cancer is still the most frequent cause of cancer death in women in developing regions despite recent advances in radiology and therapeutic modalities which allowed early cancer detection, and better management.
Despite the malignant epithelial nature of invasive breast carcinoma, recent studies have focused on the interaction between tumor cells and the tumor stroma.
Much effort has been devoted to determine how the stromal cellular components initiate and promote cancer development. Furthermore, recent progress has also highlighted the importance of noncellular components, especially the ECM, during cancer progression.
CD10 is one of the emerging novel stromal markers. It is the prototype of the matrix metalloproteinases (MMPs) family. It is a membrane-bound zinc-dependent endopeptidase that is normally expressed in various tissues. In the breast tissue, CD10 is considered a specific marker of the myoepithelial cells.
The present study aimed at immunohistochemical detection of stromal CD10 expression in invasive breast carcinomas and correlated its expression with the different clinicopathological parameters.
To achieve this aim, 60 female patients with primary invasive breast carcinoma of no special type (IC-NST) were retrospectively retrieved from the files of the Pathology and the Oncology Departments, Main University Hospital, Faculty of Medicine, Alexandria during the period from January 2004 to July 2011. The Formalin-fixed paraffin-embedded tissue specimens were cut and stained with Hematoxylin and Eosin (H&E) stain, CD10, and HER2/neu antibodies.
Data on ER and PR expression were retrieved from the archives of the Pathology department and reviewed according to both ASCO-CAP guideline recommendations and Allred scoring system. According to the hormonal receptor expression and HER2/neu status, the molecular subtype was determined.